Albert Lowe
Stock Analyst at Craig-Hallum
(3.86)
# 1,934
Out of 5,078 analysts
144
Total ratings
43.5%
Success rate
8.4%
Average return
Main Sectors:
Stocks Rated by Albert Lowe
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SPRB Spruce Biosciences | Reiterated: Buy | $140 | $45.15 | +210.08% | 4 | Sep 30, 2026 | |
| RZLT Rezolute | Upgraded: Buy | $4 → $7 | $3.86 | +81.58% | 16 | Sep 29, 2026 | |
| CMPX Compass Therapeutics | Reiterated: Buy | $8 | $0.761 | +951.25% | 7 | Sep 23, 2026 | |
| CRDF Cardiff Oncology | Reiterated: Hold | n/a | $0.9073 | - | 14 | Sep 15, 2026 | |
| LCTX Lineage Cell Therapeutics | Reiterated: Buy | n/a | $1.00 | - | 8 | Jul 14, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | n/a | $3.47 | - | 11 | Jul 6, 2026 | |
| PVLA Palvella Therapeutics | Reiterated: Buy | $205 | $125.10 | +63.87% | 6 | Jun 22, 2026 | |
| SABS SAB Biotherapeutics | Reiterated: Buy | $6 | $2.84 | +111.27% | 10 | Jun 16, 2026 | |
| NGNE Neurogene | Reiterated: Buy | $65 | $23.55 | +176.01% | 7 | May 15, 2026 | |
| ACTU Actuate Therapeutics | Reiterated: Buy | $25 → $12 | $0.4752 | +2,425.25% | 9 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $19.60 | $9.57 | +104.84% | 12 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $4.01 | - | 1 | Apr 2, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | n/a | $1.54 | - | 16 | Mar 11, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $10 | $2.60 | +284.62% | 7 | Feb 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.30 | - | 6 | Jan 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $12.00 | - | 1 | Jan 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $4 | $1.27 | +214.96% | 7 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $5.74 | n/a | 1 | Jun 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $14 | $209.29 | n/a | 1 | Jun 4, 2024 |
Spruce Biosciences
Sep 30, 2026
Reiterated: Buy
Price Target: $140
Current: $45.15
Upside: +210.08%
Rezolute
Sep 29, 2026
Upgraded: Buy
Price Target: $4 → $7
Current: $3.86
Upside: +81.58%
Compass Therapeutics
Sep 23, 2026
Reiterated: Buy
Price Target: $8
Current: $0.761
Upside: +951.25%
Cardiff Oncology
Sep 15, 2026
Reiterated: Hold
Price Target: n/a
Current: $0.9073
Upside: -
Lineage Cell Therapeutics
Jul 14, 2026
Reiterated: Buy
Price Target: n/a
Current: $1.00
Upside: -
Opus Genetics
Jul 6, 2026
Reiterated: Buy
Price Target: n/a
Current: $3.47
Upside: -
Palvella Therapeutics
Jun 22, 2026
Reiterated: Buy
Price Target: $205
Current: $125.10
Upside: +63.87%
SAB Biotherapeutics
Jun 16, 2026
Reiterated: Buy
Price Target: $6
Current: $2.84
Upside: +111.27%
Neurogene
May 15, 2026
Reiterated: Buy
Price Target: $65
Current: $23.55
Upside: +176.01%
Actuate Therapeutics
May 12, 2026
Reiterated: Buy
Price Target: $25 → $12
Current: $0.4752
Upside: +2,425.25%
May 5, 2026
Reiterated: Buy
Price Target: $19.60
Current: $9.57
Upside: +104.84%
Apr 2, 2026
Reiterated: Buy
Price Target: n/a
Current: $4.01
Upside: -
Mar 11, 2026
Reiterated: Hold
Price Target: n/a
Current: $1.54
Upside: -
Feb 12, 2026
Reiterated: Buy
Price Target: $10
Current: $2.60
Upside: +284.62%
Jan 23, 2026
Reiterated: Buy
Price Target: n/a
Current: $2.30
Upside: -
Jan 12, 2026
Reiterated: Buy
Price Target: n/a
Current: $12.00
Upside: -
Nov 13, 2025
Reiterated: Buy
Price Target: $4
Current: $1.27
Upside: +214.96%
Jun 6, 2024
Reiterated: Buy
Price Target: n/a
Current: $5.74
Upside: n/a
Jun 4, 2024
Initiated Coverage: Buy
Price Target: $14
Current: $209.29
Upside: n/a